Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.
Aquaporin-4
Neuromyelitis optica spectrum disorders
Vaccination
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 12 2022
15 12 2022
Historique:
received:
18
08
2022
revised:
14
10
2022
accepted:
24
10
2022
pubmed:
5
11
2022
medline:
3
12
2022
entrez:
4
11
2022
Statut:
ppublish
Résumé
Neuromyelitis optica spectrum disorder (NMOSD) is rarely reported following Coronavirus disease 2019 (COVID-19) vaccination. We identified 16 cases of new onset NMOSD with positive aquaporin-4 IgG (AQP4-IgG) following COVID-19 vaccination. Transverse myelitis was the most common clinical presentation (75%). Most patients received high dose steroids for acute treatment and maintenance therapy was started in 12 patients (75%). Twelve patients (75%) had improvement of their symptoms at the time of discharge or follow-up. The included cases share similar epidemiology and natural course to non-vaccine related cases. Clinicians should be aware of possible post-vaccination NMOSD to help with earlier diagnosis and treatment.
Identifiants
pubmed: 36332464
pii: S0165-5728(22)00189-8
doi: 10.1016/j.jneuroim.2022.577994
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Autoantibodies
0
Aquaporin 4
0
Immunoglobulin G
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577994Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.